Monty Rakusen Summary Following my coverage on Teradyne (NASDAQ:TER) in Nov’23, which I recommended a hold rating as I was not sure when TER would start to print positive growth. This post is to provide an update on my thoughts on the business and stock. I upgraded my rating from hold to buy as the outlook for a recovery is much more clear in 1Q24. Specifically, management has put out very encouraging 2Q24 guidance, and I have turned more bullish on the underlying AI tailwind impact on TER. Investment thesi ...